[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Edgewise Therapeutics insider Russell Alan J reported multiple equity transactions on 08/12/2025. He acquired 5,781 shares via vesting of RSUs and sold 1,907 shares in a sell-to-cover to satisfy tax withholding at an average sale price of $13.3924 per share (individual sale prices ranged $13.36–$13.49). After these transactions he beneficially owns 23,400 shares.

The filing also shows newly granted compensation awards: 5,781 RSUs vesting in four equal annual installments beginning 08/12/2025, 28,125 RSUs vesting in four equal annual installments beginning 08/12/2026, and a stock option to purchase 168,750 shares at an exercise price of $13.39 per share exercisable beginning 09/12/2025 with a 08/12/2035 expiration. The report identifies Russell as Chief Scientific Officer and a director.

Positive

• Comprehensive disclosure of RSU grants, option awards, and sell-to-cover transactions provides transparency.
• Long-term incentives granted (RSUs and 10-year option) align executive compensation with shareholder interests.
• Sell-to-cover was limited to tax withholding and not a discretionary large sale.

Negative

• Potential dilution from sizable option (168,750 shares) and RSU pools if fully vested/exercised.
• Material share creation could increase share count over multiple years, impacting per-share metrics if exercised/issued.

Insights

Compensation & Governance Analyst

TL;DR: Executive received standard equity compensation and completed a routine sell-to-cover; this is typical for management equity programs.

The report documents non-discretionary and discretionary equity awards consistent with executive compensation: two RSU grant tranches (5,781 and 28,125 RSUs) with multi-year vesting schedules and a sizable stock option (168,750 shares) with a $13.39 exercise price and a ten-year term. The sell-to-cover of 1,907 shares relates solely to tax withholding on RSU vesting and was executed at an average of $13.3924 per share. These items are material to insider dilution and potential future share supply if options are exercised, but they are recorded as routine compensation rather than transactional dispositions for liquidity.

Securities/Insider Transactions Specialist

TL;DR: Filing accurately discloses vesting/option mechanics and a tax-related share sale; no unusual trading or large dispositions reported.

The Form 4 shows the reporting person acquired 5,781 shares via RSU vesting and sold 1,907 shares in a sell-to-cover. The option grant vests monthly after a one-month cliff and expires in 2035, which is standard for long-term incentive design. The filing includes an earlier 1,005-share ESPP purchase. All positions are reported as direct ownership. From a compliance perspective, the disclosure is complete and consistent with Section 16 reporting norms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Alan J

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		M		5,781	A	$0.00	25,307(1)	D
Common Stock	08/12/2025		S		1,907(2)	D	$13.3924(3)	23,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0.00	08/12/2025		M			5,781	(4)	08/12/2034	Common Stock	5,781	$0.00	17,344	D
Restricted Stock Units	$0.00	08/12/2025		A		28,125		(5)	08/12/2035	Common Stock	28,125	$0.00	28,125	D
Stock Option (Right to Buy)	$13.39	08/12/2025		A		168,750		(6)	08/12/2035	Common Stock	168,750	$0.00	168,750	D

Explanation of Responses:

1. Includes 1,005 shares purchased on May 15, 2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

2. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

3. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

5. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

6. 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

	/s/ John R. Moore, Attorney-in-Fact for Russell Alan J	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Russell Alan J receive according to the EWTX Form 4?

The filing shows 5,781 RSUs28,125 RSUs vesting beginning 08/12/2026, and a stock option for 168,750 shares with a $13.39 exercise price and expiration in 2035.

Why were 1,907 shares of EWTX sold by Russell Alan J?

The 1,907 shares were sold in a sell-to-cover transaction to satisfy statutory tax withholding obligations tied to RSU vesting; this was not a discretionary sale.

What is the post-transaction beneficial ownership reported for Russell Alan J?

After the reported transactions, the Form 4 states the reporting person beneficially owns 23,400 shares of Edgewise Therapeutics common stock.

What were the prices for the sold shares and how were they reported?

The filing reports an average sale price of $13.3924 per share with individual sale prices ranging from $13.36 to $13.49; the filer offered to provide the breakdown on request.

When do the option and RSU vesting schedules begin?

The 5,781 RSUs vest in four equal annual installments starting 08/12/2025; the 28,125 RSUs vest in four equal annual installments starting 08/12/2026; the option vests 1/48th monthly beginning 09/12/2025.